Skip to main content

Silence Therapeutics PLC (SLN)

NASDAQ: SLN · IEX Real-Time Price · USD
0.22 (0.86%)
At close: Dec 3, 2021 4:00 PM
-0.34 (-1.32%)
After-hours:Dec 3, 2021 4:00 PM EST

Company Description

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications.

The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.

It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.

The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases.

It has collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders.

The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform.

The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Silence Therapeutics PLC
Silence Therapeutics Logo
CountryUnited Kingdom
CEODavid Solomon

Contact Details

72 Hammersmith Road
London W14 8TH
United Kingdom
Phone44 20 3457 6900

Stock Details

Ticker SymbolSLN
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1479615

Key Executives

Mark Andrew RotheraPresident, Chief Executive Officer and Executive Director
Dr. Giles V. Campion M.D.Executive Vice President, Head of Research & Development, Chief Medical Officer and Executive Director
Craig A. Tooman M.B.A., MBAChief Financial Officer
Gem Gokmen HopkinsHead of IR and Corporate Communications
Dr. Barbara A. RuskinSenior Vice President, General Counsel and Chief Patent Officer
Linnea ElringtonVice President and Head of Human Resources
Dr. John Strafford Ph.D.Senior Vice President of Business Development, Alliance Management and New Product Development
Jørgen WittendorffSenior Vice President and Head of Manufacturing
Dr. Marie Wikstrom Lindholm Ph.D.Senior Vice President and Head of Molecular Design

Latest SEC Filings

Nov 26, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 16, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 1, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Oct 25, 2021EFFECTNotice of Effectiveness
Oct 22, 2021424B5Prospectus [Rule 424(b)(5)]
Oct 21, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Oct 21, 2021EFFECTNotice of Effectiveness
Oct 21, 2021EFFECTNotice of Effectiveness
Oct 20, 2021CORRESPCorrespondence
Oct 20, 2021UPLOADSEC-generated letter
View All SEC Filings